ATTR Amyloidosis — Deal Benchmarks & Valuation
Market Analysis
ATTR Amyloidosis is one of the most actively transacted indications in metabolic licensing. Phase 2 deals for attr amyloidosis carry a median total deal value of $3.2B, with upfront payments ranging from $368M to $961M. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones.
Milestone structures for attr amyloidosis deals allocate $451M to development milestones, $551M to regulatory milestones, and $1.5B to commercial milestones. Royalty rates range from 14.5% to 26.5% at the base tier, with tiered escalation reaching 18.5%-30.5% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for attr amyloidosis licensing?
What royalty rates are standard for attr amyloidosis deals?
How are attr amyloidosis deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.